ANI projects $1.08B-$1.14B 2026 revenue as it revises Cortrophin to $520M-$540M amid gout sales force expansion (NASDAQ:ANIP)
· seekingalpha.com
ANI Pharmaceuticals (ANIP) Q2 2026 earnings call: record revenue/EBITDA, Cortrophin guidance trimmed, gout expansion ramps, Q4 outlook.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...